$297 Million is the total value of Omega Fund Management, LLC's 16 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Imago Biosciences | $108,523,595 | +138.9% | 3,018,737 | 0.0% | 36.58% | +119.8% | ||
| REPL | Sell | Replimune Group | $91,441,123 | +23.5% | 3,361,806 | -21.6% | 30.82% | +13.6% |
| NUVB | Nuvation Bio | $28,938,893 | -14.3% | 15,072,340 | 0.0% | 9.75% | -21.1% | |
| MORF | Morphic Holding | $15,989,090 | -5.5% | 597,723 | 0.0% | 5.39% | -13.0% | |
| ALPN | Alpine Immune Sciences | $14,917,413 | +2.1% | 2,029,580 | 0.0% | 5.03% | -6.0% | |
| Cincor | $7,853,790 | -57.3% | 560,985 | 0.0% | 2.65% | -60.7% | ||
| KRON | Kronos Bio | $6,185,619 | -51.6% | 3,818,283 | 0.0% | 2.08% | -55.5% | |
| IKNA | Ikena Oncology | $5,982,667 | -25.1% | 2,249,123 | 0.0% | 2.02% | -31.1% | |
| PRTK | Paratek Pharmaceuticals | $3,686,221 | -27.2% | 1,971,241 | 0.0% | 1.24% | -33.0% | |
| Theseus Pharmaceuticals | $3,543,165 | -14.1% | 711,479 | 0.0% | 1.19% | -21.0% | ||
| SANA | Sana Biotechnology, Inc. | $3,332,813 | -34.2% | 843,750 | 0.0% | 1.12% | -39.4% | |
| IMUX | Immunic Inc | $2,503,424 | -55.7% | 1,788,160 | 0.0% | 0.84% | -59.2% | |
| SPRB | Spruce Biosciences | $2,333,904 | -21.2% | 2,161,022 | 0.0% | 0.79% | -27.4% | |
| Syros Pharmaceuticals | $902,059 | -44.2% | 251,270 | 0.0% | 0.30% | -48.7% | ||
| JNCE | Jounce Therapeutics | $305,819 | -52.6% | 275,513 | 0.0% | 0.10% | -56.4% | |
| Senti Biosciences, Inc. | $276,067 | -35.0% | 195,792 | 0.0% | 0.09% | -40.4% | ||
| EPIX | Exit | ESSA Pharma | $0 | – | -328,196 | -100.0% | -0.22% | – |
| OMEG | Exit | Omega Alpha SPAC | $0 | – | -501,000 | -100.0% | -1.82% | – |
| GOSS | Exit | Gossamer Bio | $0 | – | -1,500,000 | -100.0% | -6.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.